Background: Objective of current study was to compare between intramuscular (IM) and intravenous (IV) magnesium sulfate regimen in terms of efficacy, side effects, maternal and fetal outcome. Methods: A prospective study was performed on 82 patients from September 2008 to January 2010 and comparison was made between IV and IM group, each group consisting of 17 patients of eclampsia and 24 patients of severe preeclampsia. IV group received continuous IV magnesium sulfate (IV MgSO 4 ) consisting of 4gm of loading dose, administered over 15 minutes followed by maintenance dose of 2gm/hour. The IM group received intramuscular magnesium sulfate (IM MgSO 4 ) according to Pritchard regimen. Results: Recurrence of convulsion in was found in 1/17 (5.88%) of eclamptic patients in IV and 1/17 (5.88%) in IM group which is statistically not significant (P = 1).There was no occurrence of convulsion in any of the cases having severe eclampsia in either group. There was statistically no significant difference in maternal death between the two groups (IM = 1/41(2.43%) and no mortality in IV group, P = 0.314). Statistically higher incidence (P = 0.034) of sign of impending toxicity such as loss of patellar reflex was seen in IM group as compared to IV group. Other signs of toxicity such as oliguria, respiratory rate depression though more in IM group, were statistically insignificant. There were no significant differences in other measures of serious maternal morbidity, in perinatal morbidity or mortality. Conclusions: Both the groups are comparable in terms of control and prevention of recurrence of convulsions, maternal and perinatal morbidity and mortality.
INTRODUCTION
Eclampsia and preeclampsia are important causes of morbidity and mortality during child birth and puerperium. Eclampsia alone accounts for approximately 50000 maternal deaths worldwide annually. 1 Incidence of eclampsia is one in 2000 deliveries in developed countries and one in 50 to 500 deliveries in developing countries. 2 The WHO notes that high blood pressure during pregnancy (preeclampsia and eclampsia) was one of the major direct cause of maternal deaths globally and its contribution in 2014 was 14%. 3 Hypertension and its complications are the third leading cause of pregnancyrelated deaths, superseded only by hemorrhage and associated with increased risks of placental abruption, acute renal failure, cerebrovascular and cardiovascular complications, disseminated intravascular coagulation, and maternal death. 4 In many developing countries like ours, particularly in rural areas; eclampsia may present for treatment in deep coma after many fits at home. Amongst the principles of management of eclampsia the first and the foremost is the control of convulsions. The results of collaborative eclampsia trial suggested that magnesium sulfate (MgSO 4 ) is the drug of choice for routine anticonvulsant management of women with eclampsia rather than diazepam and phenytoin. 5 The major breakthrough in the management of eclampsia came when Dr. J. A. Pritchard published his standardized treatment protocol in 1984. His protocol for management is popularly known as "Pritchard regimen". 6 Zuspan and Sibai Baha both have proposed protocol which consists of continuous infusion of magnesium sulfate in which toxicity caused due to MgSO 4 can be kept under control and complications due to toxicity could be prevented. Ekele BA, Badung SL in 2002 concluded that the routine estimation of magnesium cation is not necessary. It is suggested that serum estimation be limited to cases where clinical monitors suggest toxicity. 7 Most of the health centers in world administer MgSO 4 by continuous IV infusion because the IV route for MgSO 4 administration has some advantage over IM MgSO 4 in terms of easy administration, less painful to patient and mean magnesium level can be easily controlled but in India most medical centers prefer IM administration as described by Pritchard because in poor resource sets ups giving IV magnesium sulfate is not practical due to nonavailability of infusion sets, too busy nursing staff, taking sample for serum magnesium level at frequent interval is not cost effective. This encouraged us to do a study where both the route for MgSO 4 administration were compared and magnesium toxicity was measured by clinical parameters so that an institutional study might help the primary and other referral units to use MgSO 4 without any fear and delay.
METHODS
The study was conducted in Lala Lajpat Rai medical college, Meerut .This hospital is a tertiary referral centre and serves an indigent population from poor socioeconomic conditions. The primary aim of the study was to compare both the groups in terms of prevention of occurrence of convulsion in case of severe preeclampsia and recurrence of convulsion in case of eclampsia and other maternal complications.
The secondary outcome measures for this study were -To compare maternal and perinatal outcomes in between the two groups. Maternal outcome include -mode of delivery. Perinatal outcomes include -APGAR score, birth weight, perinatal mortality and rate of neonatal care unit admission. Inclusion criteria included women with severe proteinuric hypertension where decision had been made to deliver or was 24 hours or less postpartum and where any one of following criteria was met: 1. Premonitory symptoms like headache, visual disturbance, persistent epigastric pain, oliguria or abnormal biochemical findings: platelet count <100x10 9 , ALT >50 IU/L, markedly increased creatinine >2 mg/dl. 2. Severe hypertension (160/110 mmHg) with proteinuria of at least 2+ assessed by semi quantitative dipstick method. 3. Eclampsia: Eclampsia was diagnosed by taking history of generalized tonic clonic convulsions with or without elevated blood pressure and proteinuria (by dipstick method) in the absence of any underlying seizure disorders after 20 weeks of gestational age. All cases of antepartum, intrapartum and postpartum eclampsia, presenting in obstetric emergency (labour room) were included in the study. Patient with severe preeclampsia or eclampsia who had renal failure, severe pulmonary edema with respiratory failure, or hydatiform mole, diabetes mellitus, thyrotoxicosis, epilepsy, having received magnesium sulfate and/or other anticonvulsant before coming to our hospital, cerebrovascular accident and Disseminated Intravascular Coagulation (DIC) were excluded from the study. The patients enrolled were classified into two groups.
IM and IV group each having 41 patients (17 of eclampsia & 24 of severe preeclampsia) IV group received IV continuous infusion of 4gm MgSO 4 in 100 ml Ringer lactate given within 20 minutes followed by maintenance dose 2gm/hour by infusion pump. IM group was given intra muscular magnesium sulfate according to Pritchard regimen -4gm 20% IV MgSO 4 and 10gm IM (5gm in each buttocks) as loading dose followed by maintenance dose of 5gm IM magnesium sulfate in alternate buttock every 4 hours. In both groups MgSO 4 was given till 24 hours after delivery or 24 hours after the last fit which ever was later. In both the groups if convulsions occurred within four hours after the loading dose then it was said to be recurrence of convulsions and additional dose of 2gm IV slowly magnesium sulfate was given and previous dose schedule were continued. Each case was monitored before giving each maintenance dose, for any evidence of magnesium toxicity, by observing knee jerk reflex, urinary output and respiratory rate. By patient"s condition other clinical parameters were checked and guidelines for management of eclampsia were followed. Maintenance doses were deferred if knee jerk reflex was absent, or urine output <100 ml in 4 hours or respiratory rate <16/min. In all cases detailed history regarding high Blood Pressure (BP) recordings and medications taken, headache, blurring of vision, epigastric pain, number of convulsions, history of preeclampsia/eclampsia in previous and present pregnancy were noted. General physical examination included assessing patient"s vital signs, blood pressure recording, pallor, edema, cyanosis and systemic examination included respiratory, cardiovascular and neurological examination. Obstetrical, pelvic examination and bishop scoring was done. Laboratory investigations done were blood group and Rh type, hemogram, platelet count, liver function tests, kidney function tests, serum electrolytes, coagulation profile and fundus examination and urine examination for protein. After stabilization of the patient, induction or augmentation of labor was done in all cases of antepartum and intrapartum eclampsia. If diastolic BP was higher than 110 mmHg, oral nifidipine 10 mg in case of severe preeclampsia and sublingual nifidipine in case of eclampsia was used. Cesarean section was performed for obstetrical indication. Birth weight of the baby, APGAR score and neonatal outcome were recorded. Serum magnesium level could not be measured because it was not cost-effective.
Statistics
A comparative analysis was made between the two groups. Data were analysed using Statistical Package for Social Sciences (SPSS) version 15.0, all the nonparametric data (proportional data) has been shown as number and percentages, parametric data as mean and standard deviation. Intergroup differences have been calculated using Pearson"s Chi square test for proportions and independent sample"s "t" test or student"t" for parametric data. The confidence limit of the study was kept at 95%, a P value ≤0.05 was taken as a level of statistically significant difference.
RESULTS
There were total 2739 deliveries in the hospital during the study period. The incidence of eclampsia in our hospital was 1.24 and of severe preeclampsia was 1.75%. Such high incidence is due to referral from periphery as ours is a tertiary care centre. Patient characteristics and study parameters are presented in Table 1 . 13 .735 ± 7 hours in IM group and 13.06 ± 5.9 hours in IV group. The mean dose of magnesium sulfate given in IV and IM group was 63.27 ± 16.62 gm and 65.93 ± 18.12 gm, respectively (statistically not significant). As shown in Table 4 68.29% of patients delivered by vaginal route in IV and 75.6% in IM group. Table 2 were found more in IM group 16/41 (39.02%) as compared to IV group 5/41 (12.19% ). Loss of patellar reflex was present in 10/41 (24.39%) subjects of IM group and only in 3/41 (7.31%) in IV group and this was statistically significant. P = (0.034). Rest of the signs of impending toxicity (like oliguria, RR <16/min, local site complications) though more in IM group were statistically insignificant. Table 3 . We defined recurrence of convulsions if it occurred 30 minutes after the loading dose. Recurrence of convulsion was found in 1 (5.88%) patient in IV and 1 (5.88%) patients in IM group. Each episode was treated with additional 2 gram of magnesium sulfate. In this study none of the patient with severe preeclampsia developed convulsion after the therapy. Obstetric complications as shown in Table 3 during labour and delivery (Like atonic PPH and abruption and RD) were 14.63% and 17.07% in IV and IM group respectively (statistically not significant P = 0.762). Other complications (Acute renal failure, pulmonary edema, thrombocytopenia) were (9.75%) and (17.07%) in IV and IM group respectively. 1/41 (2.43%) patient expired in IM group but there was no mortality in IV group. Table 5 shows a higher Perinatal mortality in IM group when compared to IV (17.07% in IV 13.95% in IM) but it was insignificant. Mean baby weight at birth was almost similar in both group; (2.34 ± 6 kg) in IV and 2.31 ± 0.75 kg in IM group. APGAR Scores and rate of admissions in neonatal intensive care unit were found to be comparable in both the groups. 
Signs of impending toxicity as in

DISCUSSION
The use of MgSO 4 for seizure control and prophylaxis has been shown to be efficacious in women with eclampsia and severe preeclampsia. The routine use of seizure prophylaxis in women with mild preeclampsia has never been supported by evidence. It has been found that the routine use of magnesium sulfate therapy is not without complications. recurrence rate reported in collaborative eclampsia trial 15 using Pritchard"s regimen ranged between 5.7 and 13.2%. There was no occurrence of convulsion in any subject with severe preeclampsia. Coetzee et al. 13 found occurrence of convulsion rate of 0.3% in severe eclampsia group after receiving IV magnesium sulfate.
Chinayon P 16 (1998) and Ekele 7 (2005) suggested that, clinical assessment of knee jerk, respirations and urine output is adequate to monitor maternal magnesium toxicity without the need to determine actual maternal serum levels. In this study we also evaluated the impending signs of toxicity clinically; loss of patellar reflex, which was higher in IM 10/41 (24.39%) as compared to IV 3/41(7.31) group, which was significant, (P = 0.034). Oliguria was less in IV than IM group 2.43% vs. 7.31% (P = 0.396). Local site abscess was seen in 1 case of eclampsia IM group which was managed conservatively. No patient in IV group had respiratory depression, or any local site complication such as phlebitis. Overall signs of impending toxicity were more common in IM group compared to IV group (39.02% IM/12.19% IV) but it was not statistically significant. Chissell S 17 (1994) described magnesium toxicity in 1/8 (12.5%) cases of IV group and none in IM group. Our study Abruptio 3 (7.31%) 3 (7.31%) Pulmonary oedema 1 (2.43%) 0 Thrombocytopenia 4 (9.75%) 4 (9.75%) ARF 0 3 (7.31%) PPH 3 (7.31%) 3 (7.31%) RD 0 1 (2.43%) HELLP = Hemolysis elevated liver enzymes low platelet count, PPH = Post-partum haemorrhage, RD = Respiratory depression, ARF = Acute renal failure, DIC = Disseminated intravascular coagulopathy Common complications observed in our patients were abruptio atonic-PPH, thrombocytopenia, ARF, pulmonary-oedema. There were 3/41 (7.31%) in IV and similar number 3/41 (7.35%) in IM group who had PPH. Abruptio was found in 3/41 (7.31%) in IV and 3/41 (7.31%) in IM group. Thrombocytopenia was seen equally 4/41(9.57%) both group. 3/41 (7.31%) patients had ARF in IM group but none in IV group.1/41(2.43%) patient had pulmonary oedema in IV group no such complication was present in IM group. None of the patient in either group had bed sores, injection site cellulitis, hematuria, post-partum psycho. In our study 24.39% in IV group and 34.14% in IM group had complications during labour and delivery which was not statistically significant. Comparison of complications with study of Sardesai et al. 18 (2003) is shown in Table 6 .
One patient (2.43%) of eclampsia expired after respiratory depression, she was shifted to ICU but expired despite of intensive management. No such were found in IV group. Thus maternal mortality rate was 1.22%. Chowdhary et al. 19 reported maternal mortality rate of 5% in the IM and 3.3% in the IV groups. Mode of delivery in most of the cases was by vaginal route-28/41 patients (68.29%) in IV group & 31/41 patients (75.60%) in IM group. In eclampsia (17 each of IM and IV group) patients more common mode of delivery was by vaginal route in 24/34 (70.58%), LSCS was done in 10(29.41%) women of eclampsia. Also among severe preeclampsia (24 each of IM and IV group) commoner route of delivery was vaginal route 35/48 (72.91%) and by LSCS in 13/48 (27.08%). Cesarean section rate in collaborative eclampsia trial 15 was 66 to 72% using standard Pritchard"s regimen. In study of Chissell S 17 caesarean section rate was 4/8 in IV group and 3/9 in IM group respectively.
Neonatal outcome depends on severity of associated intrauterine growth retardation (IUGR), gestational age, birth weight and the level of facilities in NICU. There were 34 live deliveries in IM group as compared to 37 in IV group and there were no still births. Statistically, there was no significant difference in two groups. Perinatal mortality was 7/41 (13.95%) in IV group and 6/43 (17.07%) in IM group. Overall perinatal mortality in our study was 15.47%. Sardesai, 18 Pritchard 6 showed 20.22%, 33.83% perinatal mortality respectively. Collaborative eclampsia trial 15 using standard dose regimen found perinatal mortality rate of 24-26% and birth asphyxia of 44-48% in eclampsia. Chissell S 17 showed 1/8 and 1/9 stillbirth in both IV and IM severe eclampsia group respectively. It was seen that subjects in IM group had no significant difference as regard babies with low APGAR score as compared to subjects in IV group (P = 0.751). In our study there were needs of NICU admission in 10 live births (14.92%) in IV group 9 (13.43%) in IM group.
In the study of Shela Noor 20 et al. using Pritchard regimen, 3.77% of eclamptic and 10% of severe preeclampsia babies required nursery admission. The mean baby weight in IM group was 2.31 ± 0.75 kg as compared to 2.34 ± 6 kg in IV group, thus showing no significant difference between two groups (P = 0.839). Amongst patients of eclampsia 35.29% of live babies were of birth weight ≥2.5 kg and among severe preeclampsia 45.83% of live babies were of birth weight ≥2.5.
CONCLUSION
We can conclude from above study that Pritchard regimen and IV continuous magnesium sulfate regimen Kanti V et al. Int J Reprod Contracept Obstet Gynecol. 2015 Feb; 4(1):195-201 International Journal of Reproduction, Contraception, Obstetrics and Gynecology Volume 4 · Issue 1 Page 201 are equally effective in terms of control & prevention of recurrence of convulsions. Signs of magnesium toxicity (except for loss of patellar reflex which was more in IM group) was almost similar in both regimen. Overall perinatal outcome was equal in both the groups. IM regimen has the disadvantage of painful injections, but it has the advantage of great convenience. In settings where pumps for IV infusion are not readily available and, the nursing staff may be too busy to provide the continuous monitoring required. The IM route, where a dose is only given; once the reflexes, respiration and urine output have been checked, is likely to be safer. There is no significant difference in these two regimens, IM dose can be given preferentially where frequent monitoring of magnesium level is not practical.
